Our Top 5 Microcap Stocks
Microcap stocks tend to be an under-researched area… Which increases the odds of discovering attractive investment opportunities.

Just like these 5 which appear to be in an excellent position to see a surge in share price.
>>> See All 5 Here
pixel

VRPX Insider Trading

Insider Ownership Percentage: 28.70%
Insider Buying (Last 12 Months): $113,401.44
Insider Selling (Last 12 Months): $0.00

Virpax Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Virpax Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Virpax Pharmaceuticals Share Price & Price History

Current Price: $0.75
Price Change: Price Decrease of -0.05 (-6.25%)
As of 12/9/2022 01:00 AM ET

This chart shows the closing price history over time for VRPX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Virpax Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/24/2022Jerrold SendrowDirectorBuy4,500$1.29$5,805.009,006View SEC Filing Icon  
5/18/2022Anthony P. MackCEOBuy75,750$1.34$101,505.00252,562View SEC Filing Icon  
5/18/2022Eric FloydDirectorBuy4,479$1.36$6,091.448,018View SEC Filing Icon  
11/22/2021Jerrold SendrowDirectorBuy3,900$3.92$15,288.00View SEC Filing Icon  
11/18/2021Anthony P. MackCEOBuy25,125$3.99$100,248.75View SEC Filing Icon  
2/17/2021Thani JambulingamDirectorBuy100$7.16$716.00100View SEC Filing Icon  
See Full Table
Our Top 5 Microcap Stocks
Microcap stocks tend to be an under-researched area… Which increases the odds of discovering attractive investment opportunities.

Just like these 5 which appear to be in an excellent position to see a surge in share price.
>>> See All 5 Here
pixel

SEC Filings (Institutional Ownership Changes) for Virpax Pharmaceuticals (NASDAQ:VRPX)

15.93% of Virpax Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at VRPX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Virpax Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/15/2022Vanguard Group Inc.370,884$0.44M0.0%+8.5%3.166%Search for SEC Filing on Google Icon
11/14/2022Renaissance Technologies LLC158,322$0.19M0.0%-22.1%1.352%Search for SEC Filing on Google Icon
8/13/2022Renaissance Technologies LLC203,200$0.34M0.0%+29.8%1.735%Search for SEC Filing on Google Icon
5/13/2022Renaissance Technologies LLC156,600$0.35M0.0%N/A1.337%Search for SEC Filing on Google Icon
5/13/2022Vanguard Group Inc.341,977$0.76M0.0%+4.5%2.918%Search for SEC Filing on Google Icon
5/13/2022Warberg Asset Management LLC17,710$39K0.0%N/A0.151%Search for SEC Filing on Google Icon
5/12/2022Citigroup Inc.12,179$27K0.0%N/A0.104%Search for SEC Filing on Google Icon
11/17/2021Altium Capital Management LP271,846$1.31M0.3%N/A2.320%Search for SEC Filing on Google Icon
11/16/2021National Asset Management Inc.18,600$90K0.0%N/A0.159%Search for SEC Filing on Google Icon
11/2/2021Cambridge Investment Research Advisors Inc.19,420$93K0.0%N/A0.166%Search for SEC Filing on Google Icon
9/17/2021Virtu Financial LLC23,625$0.11M0.0%N/A0.468%Search for SEC Filing on Google Icon
8/16/2021Sabby Management LLC154,737$0.70M0.1%-22.6%3.120%Search for SEC Filing on Google Icon
8/12/2021Saltoro Capital LP17,615$80K0.0%-34.8%0.355%Search for SEC Filing on Google Icon
5/14/2021HN Saltoro Capital LP27,000$0.13M0.0%N/A0.546%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Virpax Pharmaceuticals logo
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and VRP324, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
Read More on Virpax Pharmaceuticals

Today's Range

Now: $0.75
Low: $0.68
High: $0.84

50 Day Range

MA: $0.96
Low: $0.75
High: $1.20

52 Week Range

Now: $0.75
Low: $0.68
High: $4.21

Volume

66,882 shs

Average Volume

107,995 shs

Market Capitalization

$8.79 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.6

Who are the company insiders with the largest holdings of Virpax Pharmaceuticals?

Virpax Pharmaceuticals' top insider investors include:
  1. Anthony P Mack (CEO)
  2. Jerrold Sendrow (Director)
  3. Eric Floyd (Director)
  4. Thani Jambulingam (Director)
Learn More about top insider investors at Virpax Pharmaceuticals.

Who are the major institutional investors of Virpax Pharmaceuticals?

Virpax Pharmaceuticals' top institutional shareholders include:
  1. Vanguard Group Inc. — 3.17%
  2. Renaissance Technologies LLC — 1.35%
Learn More about top institutional investors of Virpax Pharmaceuticals stock.

Which institutional investors are selling Virpax Pharmaceuticals stock?

In the last quarter, VRPX stock was sold by these institutional investors:
  1. Renaissance Technologies LLC

Which institutional investors are buying Virpax Pharmaceuticals stock?

In the last quarter, VRPX stock was acquired by institutional investors including:
  1. Vanguard Group Inc.
During the previous year, these company insiders have bought Virpax Pharmaceuticals stock:
  1. Anthony P Mack (CEO)
  2. Jerrold Sendrow (Director)
  3. Eric Floyd (Director)
  4. Thani Jambulingam (Director)
Learn More investors buying Virpax Pharmaceuticals stock.
Our Top 5 Microcap Stocks
Microcap stocks tend to be an under-researched area… Which increases the odds of discovering attractive investment opportunities.

Just like these 5 which appear to be in an excellent position to see a surge in share price.
>>> See All 5 Here
pixel